TBC1D3G
gene geneOn this page
Summary
TBC1D3G (TBC1 domain family member 3G, HGNC:29860) is a protein-coding gene on chromosome 17q12, encoding TBC1 domain family member 3G (Q6DHY5). Acts as a GTPase activating protein for RAB5.
Predicted to enable GTPase activator activity. Predicted to be located in plasma membrane.
Source: NCBI Gene 101060321 — RefSeq curated summary.
At a glance
- GWAS associations: 2
- MANE Select transcript:
NM_001291462
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:29860 |
| Approved symbol | TBC1D3G |
| Name | TBC1 domain family member 3G |
| Location | 17q12 |
| Locus type | gene with protein product |
| Status | Approved |
| Ensembl gene | ENSG00000260287 |
| Ensembl biotype | protein_coding |
| OMIM | 610810 |
| Entrez | 101060321 |
Gene structure
Transcript identifiers
Ensembl transcripts: 2 — 2 protein_coding
ENST00000569055, ENST00000959385
RefSeq mRNA: 1 — MANE Select: NM_001291462
NM_001291462
CCDS: CCDS74040
Canonical transcript exons
ENST00000569055 — 14 exons
| Exon | Start | End |
|---|---|---|
| ENSE00002578788 | 36329856 | 36329904 |
| ENSE00002585669 | 36333876 | 36334759 |
| ENSE00002587908 | 36330448 | 36330568 |
| ENSE00002594912 | 36328498 | 36328607 |
| ENSE00002601767 | 36331761 | 36331826 |
| ENSE00002602496 | 36332760 | 36332912 |
| ENSE00002607262 | 36327537 | 36327617 |
| ENSE00002611521 | 36328061 | 36328168 |
| ENSE00002615932 | 36331282 | 36331376 |
| ENSE00002624475 | 36332290 | 36332389 |
| ENSE00003507437 | 36325646 | 36325731 |
| ENSE00003510663 | 36325411 | 36325483 |
| ENSE00003527731 | 36327015 | 36327054 |
| ENSE00003733528 | 36323884 | 36323982 |
Expression profiles
Bgee: expression breadth ubiquitous, 109 present calls, max score 84.16.
Top tissues by expression
132 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 84.16 | silver quality |
| left testis | UBERON:0004533 | 82.97 | gold quality |
| right testis | UBERON:0004534 | 82.40 | gold quality |
| testis | UBERON:0000473 | 81.97 | gold quality |
| right uterine tube | UBERON:0001302 | 81.70 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 65.76 | gold quality |
| duodenum | UBERON:0002114 | 49.32 | gold quality |
| right coronary artery | UBERON:0001625 | 42.44 | gold quality |
| hindlimb stylopod muscle | UBERON:0004252 | 41.35 | gold quality |
| skeletal muscle tissue | UBERON:0001134 | 39.41 | gold quality |
| muscle tissue | UBERON:0002385 | 38.95 | gold quality |
| bone marrow | UBERON:0002371 | 38.69 | gold quality |
| smooth muscle tissue | UBERON:0001135 | 38.63 | gold quality |
| colonic epithelium | UBERON:0000397 | 37.20 | gold quality |
| fallopian tube | UBERON:0003889 | 36.88 | gold quality |
| metanephros cortex | UBERON:0010533 | 36.49 | gold quality |
| ventricular zone | UBERON:0003053 | 36.48 | gold quality |
| cortical plate | UBERON:0005343 | 36.47 | gold quality |
| bone marrow cell | CL:0002092 | 36.16 | gold quality |
| endocervix | UBERON:0000458 | 36.09 | gold quality |
| ganglionic eminence | UBERON:0004023 | 35.49 | gold quality |
| uterine cervix | UBERON:0000002 | 35.28 | gold quality |
| blood | UBERON:0000178 | 35.06 | gold quality |
| left uterine tube | UBERON:0001303 | 34.84 | gold quality |
| muscle of leg | UBERON:0001383 | 33.33 | gold quality |
| liver | UBERON:0002107 | 33.13 | gold quality |
| gall bladder | UBERON:0002110 | 32.87 | gold quality |
| placenta | UBERON:0001987 | 32.48 | gold quality |
| cortex of kidney | UBERON:0001225 | 32.46 | gold quality |
| gastrocnemius | UBERON:0001388 | 32.23 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 0.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | no | 0.35 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
19 targeting TBC1D3G, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-1250-3P | 99.96 | 70.04 | 4038 |
| HSA-MIR-335-3P | 99.93 | 73.36 | 4958 |
| HSA-MIR-4731-5P | 99.89 | 67.23 | 2537 |
| HSA-MIR-4492 | 99.87 | 68.25 | 3611 |
| HSA-MIR-130B-5P | 99.83 | 68.50 | 1888 |
| HSA-MIR-374C-5P | 99.80 | 72.06 | 2910 |
| HSA-MIR-655-3P | 99.80 | 72.19 | 2909 |
| HSA-MIR-7110-5P | 99.80 | 67.84 | 1712 |
| HSA-MIR-12130 | 99.75 | 65.47 | 452 |
| HSA-MIR-5584-5P | 99.49 | 68.22 | 2814 |
| HSA-MIR-4505 | 99.27 | 67.81 | 2678 |
| HSA-MIR-3940-5P | 99.14 | 65.26 | 493 |
| HSA-MIR-4507 | 99.14 | 65.27 | 515 |
| HSA-MIR-421 | 98.90 | 67.04 | 1883 |
| HSA-MIR-7155-5P | 98.65 | 66.14 | 1290 |
| HSA-MIR-8060 | 98.61 | 66.93 | 1187 |
| HSA-MIR-5585-5P | 97.95 | 68.80 | 1024 |
| HSA-MIR-3135A | 96.41 | 65.30 | 494 |
| HSA-MIR-548AD-3P | 94.39 | 66.04 | 350 |
Cross-species orthologs
0 orthologs
Paralogs (45): RABGAP1 (ENSG00000011454), TBC1D22A (ENSG00000054611), TBC1D22B (ENSG00000065491), TBC1D1 (ENSG00000065882), EVI5 (ENSG00000067208), TBC1D25 (ENSG00000068354), TBC1D2 (ENSG00000095383), TBC1D10A (ENSG00000099992), SGSM3 (ENSG00000100359), TBC1D17 (ENSG00000104946), TBC1D13 (ENSG00000107021), TBC1D12 (ENSG00000108239), TBC1D9 (ENSG00000109436), TBC1D30 (ENSG00000111490), TBC1D15 (ENSG00000121749), TBC1D5 (ENSG00000131374), TBC1D14 (ENSG00000132405), TBC1D8B (ENSG00000133138), TBC1D4 (ENSG00000136111), GRTP1 (ENSG00000139835), SGSM2 (ENSG00000141258), EVI5L (ENSG00000142459), TBCK (ENSG00000145348), USP6NL (ENSG00000148429), RABGAP1L (ENSG00000152061), SGSM1 (ENSG00000167037), TBC1D21 (ENSG00000167139), TBC1D2B (ENSG00000167202), TBC1D16 (ENSG00000167291), TBC1D10B (ENSG00000169221), TBC1D10C (ENSG00000175463), TBC1D28 (ENSG00000189375), TBC1D9B (ENSG00000197226), TBC1D8 (ENSG00000204634), TBC1D26 (ENSG00000214946), TBC1D3K (ENSG00000273513), TBC1D3H (ENSG00000274226), TBC1D3D (ENSG00000274419), TBC1D3L (ENSG00000274512), TBC1D3 (ENSG00000274611)
Protein
Protein identifiers
TBC1 domain family member 3G — Q6DHY5 (reviewed: Q6DHY5)
All UniProt accessions (1): Q6DHY5
UniProt curated annotations — full annotation on UniProt →
Function. Acts as a GTPase activating protein for RAB5. Does not act on RAB4 or RAB11.
Subcellular location. Cell membrane.
Post-translational modifications. Ubiquitinated by a CUL7-based E3 ligase, which leads to proteasomal degradation. Palmitoylation is required for membrane localization and protects TBC1D3 from ubiquitination.
Miscellaneous. TBC1D3 is encoded by a collection of very similar paralogs with multiple copies of each paralog, some human genomes encoding well over 50 copies depending on ethnic origin of the donor.
RefSeq proteins (1): NP_001278391* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR000195 | Rab-GAP-TBC_dom | Domain |
| IPR035969 | Rab-GAP_TBC_sf | Homologous_superfamily |
| IPR050302 | Rab_GAP_TBC_domain | Family |
Pfam: PF00566
UniProt features (12 total): sequence conflict 5, region of interest 2, lipid moiety-binding region 2, chain 1, domain 1, compositionally biased region 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q6DHY5-F1 | 60.54 | 0.25 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (2): 318, 325
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 11 (showing top):
ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN, GOMF_ENZYME_ACTIVATOR_ACTIVITY, GOMF_NUCLEOSIDE_TRIPHOSPHATASE_REGULATOR_ACTIVITY, GOMF_ENZYME_REGULATOR_ACTIVITY, WANG_RESPONSE_TO_GSK3_INHIBITOR_SB216763_UP, chr17q12, THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_RESPONDERS_28DY_DN, GOMF_MOLECULAR_FUNCTION_ACTIVATOR_ACTIVITY, WP_17Q12_COPY_NUMBER_VARIATION_SYNDROME, GOCC_ENDOSOME, GOMF_GTPASE_ACTIVATOR_ACTIVITY
GO Biological Process (0):
GO Molecular Function (2): GTPase activator activity (GO:0005096), protein binding (GO:0005515)
GO Cellular Component (3): endosome (GO:0005768), plasma membrane (GO:0005886), membrane (GO:0016020)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| GTPase activity | 1 |
| enzyme activator activity | 1 |
| GTPase regulator activity | 1 |
| binding | 1 |
| endomembrane system | 1 |
| cytoplasmic vesicle | 1 |
| membrane | 1 |
| cell periphery | 1 |
| cellular anatomical structure | 1 |
Protein interactions and networks
STRING
216 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| TBC1D3G | CDRT15L2 | A8MXV6 | 580 |
| TBC1D3G | OR4X2 | Q8NGF9 | 507 |
| TBC1D3G | CCDC144A | A2RUR9 | 479 |
| TBC1D3G | SLC35G3 | Q8N808 | 476 |
| TBC1D3G | SLC35G6 | P0C7Q6 | 476 |
| TBC1D3G | ZNF670 | Q9BS34 | 474 |
| TBC1D3G | CHCT1 | Q86WR6 | 447 |
| TBC1D3G | SPDYE4 | A6NLX3 | 447 |
| TBC1D3G | OR3A2 | P47893 | 447 |
| TBC1D3G | OR5M11 | Q96RB7 | 447 |
| TBC1D3G | ZNF669 | Q96BR6 | 432 |
| TBC1D3G | LRRC3C | A6NJW4 | 419 |
| TBC1D3G | FBXW10B | O95170 | 419 |
| TBC1D3G | KRTAP2-2 | Q9BYT5 | 419 |
| TBC1D3G | C17orf78 | Q8N4C9 | 418 |
IntAct
29 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| TBC1D3G | ZRANB1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| TBC1D3G | MDFI | psi-mi:“MI:0915”(physical association) | 0.560 |
| BAG3 | TBC1D3G | psi-mi:“MI:0915”(physical association) | 0.560 |
| PSMD2 | TBC1D3G | psi-mi:“MI:0915”(physical association) | 0.560 |
| GRB2 | TBC1D3G | psi-mi:“MI:0915”(physical association) | 0.560 |
| GEM | TBC1D3G | psi-mi:“MI:0915”(physical association) | 0.560 |
| BAG4 | TBC1D3G | psi-mi:“MI:0915”(physical association) | 0.560 |
| TBC1D3G | GTPBP3 | psi-mi:“MI:0915”(physical association) | 0.560 |
| TBC1D3G | PPM1G | psi-mi:“MI:0914”(association) | 0.350 |
| TBC1D3G | ZRANB1 | psi-mi:“MI:0915”(physical association) | 0.000 |
| TBC1D3G | MDFI | psi-mi:“MI:0915”(physical association) | 0.000 |
| BAG3 | TBC1D3G | psi-mi:“MI:0915”(physical association) | 0.000 |
| PSMD2 | TBC1D3G | psi-mi:“MI:0915”(physical association) | 0.000 |
| GRB2 | TBC1D3G | psi-mi:“MI:0915”(physical association) | 0.000 |
| GEM | TBC1D3G | psi-mi:“MI:0915”(physical association) | 0.000 |
| BAG4 | TBC1D3G | psi-mi:“MI:0915”(physical association) | 0.000 |
| GTPBP3 | TBC1D3G | psi-mi:“MI:0915”(physical association) | 0.000 |
BioGRID (10): LOC101060321 (Two-hybrid), LOC101060321 (Two-hybrid), LOC101060321 (Two-hybrid), LOC101060321 (Two-hybrid), LOC101060321 (Two-hybrid), LOC101060321 (Two-hybrid), LOC101060321 (Two-hybrid), LOC101060321 (Two-hybrid), LOC101060321 (Negative Genetic), LOC101060321 (Negative Genetic)
ESM2 similar proteins: A0A087WVF3, A0A087WXS9, A0A087X179, A0A087X1G2, A6NDS4, A6NER0, A6QPT6, B9A6J9, M3WHG5, O14771, O15482, O15553, O19110, O76081, P0C7X1, P0C7X3, P0C7X4, P35125, P48778, P48967, P79209, Q13670, Q15697, Q2TBC4, Q3T191, Q3UZD7, Q4R2Z8, Q5DRQ5, Q5SSQ6, Q5XFX8, Q69ZB3, Q6DHY5, Q6IPX1, Q6ZMN8, Q8BLR5, Q8BWA8, Q8IYF1, Q8IZP1, Q8JZW5, Q8N7G0
Diamond homologs: A0A087WVF3, A0A087WXS9, A0A087X179, A0A087X1G2, A2AWA9, A6H6A9, A6NDS4, A6NER0, B9A6J9, H2KZZ6, P0C7X1, P35125, Q2M2D7, Q5RAN1, Q5SVR0, Q66K14, Q6DHY5, Q6IPX1, Q80XC3, Q86UD7, Q8IZP1, Q92738, Q9UFV1, Q9Y3P9, A3KGB4, A6QP29, B0R0W9, B7ZAP0, O60343, O60447, O95759, O97790, P58802, P97366, Q0IIM8, Q10496, Q12317, Q12344, Q28CB1, Q3UYK3
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
0 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 0 |
| Likely benign | 0 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
0 predictions. Top by Δscore:
AlphaMissense
3581 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 17:36330520:T:C | F207L | 0.979 |
| 17:36330522:C:A | F207L | 0.979 |
| 17:36330522:C:G | F207L | 0.979 |
| 17:36332317:T:A | W286R | 0.933 |
| 17:36332317:T:C | W286R | 0.933 |
| 17:36328112:T:A | W111R | 0.920 |
| 17:36328112:T:C | W111R | 0.920 |
| 17:36327570:T:A | W78R | 0.919 |
| 17:36327570:T:C | W78R | 0.919 |
| 17:36327572:G:C | W78C | 0.897 |
| 17:36327572:G:T | W78C | 0.897 |
| 17:36330523:T:A | W208R | 0.885 |
| 17:36330523:T:C | W208R | 0.885 |
| 17:36328585:T:C | F159L | 0.884 |
| 17:36328587:C:A | F159L | 0.884 |
| 17:36328587:C:G | F159L | 0.884 |
| 17:36330521:T:C | F207S | 0.883 |
| 17:36327569:G:C | K77N | 0.875 |
| 17:36327569:G:T | K77N | 0.875 |
| 17:36328114:G:C | W111C | 0.872 |
| 17:36328114:G:T | W111C | 0.872 |
| 17:36328506:G:C | K132N | 0.871 |
| 17:36328506:G:T | K132N | 0.871 |
| 17:36328163:T:G | Y128D | 0.862 |
| 17:36328164:A:C | Y128S | 0.856 |
| 17:36330525:G:C | W208C | 0.851 |
| 17:36330525:G:T | W208C | 0.851 |
| 17:36327593:G:C | W85C | 0.845 |
| 17:36327593:G:T | W85C | 0.845 |
| 17:36332319:G:C | W286C | 0.840 |
dbSNP variants (sampled 300 via entrez): RS1156281886 (17:36314978 T>C), RS1156387044 (17:36321661 T>C), RS1156476344 (17:36317939 C>T), RS1156573549 (17:36452051 AGCG>A), RS1156739599 (17:36326258 G>A), RS1156910969 (17:36323202 G>A), RS1157026296 (17:36452759 C>A), RS1157039151 (17:36327768 C>T), RS1157051932 (17:36332362 A>C), RS1157358423 (17:36333086 C>T), RS1157518568 (17:36330610 T>G), RS1157897020 (17:36452525 G>C,T), RS1157907490 (17:36326730 C>T), RS1157956010 (17:36332675 C>T), RS1158091702 (17:36258681 ACT>A)
Disease associations
OMIM: gene MIM:610810 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
2 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST005951_15 | Body mass index | 3.000000e-13 |
| GCST009159_13 | Blood protein levels | 7.000000e-21 |
EFO canonical traits (2, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0004340 | body mass index |
| EFO:0004747 | protein measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
9 total (human), top 9 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| sodium arsenite | decreases expression, increases abundance | 1 |
| benzo(e)pyrene | decreases methylation | 1 |
| indeno(1,2,3-cd)pyrene | decreases expression | 1 |
| abrine | increases expression | 1 |
| Arsenic | increases abundance, decreases expression | 1 |
| Estradiol | affects cotreatment, decreases expression | 1 |
| Methapyrilene | decreases methylation | 1 |
| Smoke | decreases expression | 1 |
| Aflatoxin B1 | decreases methylation | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.